VisualAbstract Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Cytogenetic Subgroup Analysis from POLLUX | 2 Minute Medicine
ADD Velcade, Revlimid, and dex (VRd) | Int Myeloma Fn
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Study design and MRD time-points. RD: Lenalidomide-Dexamethasone, CTX:... | Download Scientific Diagram
Dosing and Administration for the NINLARO® (ixazomib) Regimen
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
DRd Trial Design & Efficacy | REVLIMID® (lenalidomide)
Lenalidomide with Low- or High-Dose Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Aftermath of Revlimid of primary benefit multiple myeloma
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma - Conquer: the journey informed
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma | MedPage Today
REVLIMID® (lenalidomide) - Official Patient Website
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma - The ASCO Post
Multiple Myeloma Support + Trials
Relapsed Multiple Myeloma Treatment Results | KYPROLIS® (carfilzomib)
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Pts: Results of the Spanish GEM2014MAIN Trial
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Revlimid 25mg Capsule
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile - Medwave
